News - Ipsen, Somatuline

Filter

Current filters:

IpsenSomatuline

Popular Filters

Ipsen sales up in first quarter, boosted by specialty care

Ipsen sales up in first quarter, boosted by specialty care

30-04-2014

French drugmaker Ipsen has reported sales of 305.9 million euros ($423 million) for the first quarter…

Business FinanceBusiness FinanceDecapeptylDysportEURFinancialFranceIpsenPfizerPharmaceuticalSomatulineTriptorelin

Ipsen, a good European mid-cap to watch, says US analyst

Ipsen, a good European mid-cap to watch, says US analyst

27-01-2014

Most American investors are familiar with large European drugmakers like Sanofi and Novartis but the…

FinancialIpsenOncologyPharmaceuticalResearchSomatulinetasquinimod

Ipsen implements new US governance to prepare for Somatuline launch in oncology

Ipsen implements new US governance to prepare for Somatuline launch in oncology

22-01-2014

French drugmaker Ipsen (Euronext: IPN) has announced new governance in the USA following its decision…

BoardroomIpsenOncologyPharmaceuticalSomatulineUSA

Ipsen reveals positive results for Somatuline

Ipsen reveals positive results for Somatuline

17-01-2014

French drugmaker Ipsen (Euronext: IPN) has announced that Somatuline Autogel/Somatuline Depot (lanreotide)…

FranceIpsenOncologyPharmaceuticalResearchSomatuline

Ipsen and GW Pharma to promote Sativex in Latin America; Ipsen will ‘go it alone’ for Somatuline

Ipsen and GW Pharma to promote Sativex in Latin America; Ipsen will ‘go it alone’ for Somatuline

14-01-2014

French drugmaker Ipsen (Euronext: IPN) and UK-based GW Pharmaceuticals (Nasdaq: GWPH) have entered into…

FranceGW PharmaceuticalsIpsenLicensingPharmaceuticalSativexSomatuline

Highlights from European Cancer Congress on Kadcyla, Yervoy, Erbitux and Somatuline

30-09-2013

A host of new oncology data was presented at the European Cancer Congress in Amsterdam, the Netherlands,…

Bristol-Myers SquibbErbituxEuropeIpsenKadcylaMerck KGaAOncologyPharmaceuticalResearchRocheSomatulineYervoy

Ipsen hopes study results could lead to additional Somatuline indication

17-09-2013

French drugmaker Ipsen (Euronext: IPN) has released positive clinical trial results for the treatment…

EuropeIpsenNeurologicalPharmaceuticalResearchSomatuline

Trial finds Ipsen's tumor drug Somatuline superior to placebo in delaying disease progression

11-07-2013

French drugmaker Ipsen (Euronext: IPN) has announced positive results from its Phase III study of Somatuline…

EuropeIpsenOncologyPharmaceuticalResearchSomatuline

Ipsen reports mixed Ph III results with Somatuline Autogel in patients with acromegaly

18-06-2013

French drugmaker Ipsen (Euronext: IPN) announced the results of an international Phase IIIb study, PRIMARYS,…

IpsenPharmaceuticalRare diseasesResearchSomatuline

Global neuroendocrine carcinoma market to reach $475 million by 2019; report

04-07-2012

The global Neuroendocrine carcinoma therapeutics market was worth $127 million in 2011 and now the market…

AvastinBioSynthemaIpsenLutatheraMarkets & MarketingOncologyPharmaceuticalRocheSomatuline

Teijin and Ipsen's Somatuline cleared in Japan

01-07-2012

Japanese drugmaker Teijin Pharma (TYO: 3402) revealed last Friday that it has received manufacturing…

Asia-PacificIpsenPharmaceuticalRare diseasesRegulationSomatulineTeijin

Back to top